Why it matters: NICE hypertension guidance states there is insufficient evidence of its effectiveness to determine its suitability for use in resistant hypertension. Whilst aliskiren has shown comparable efficacy to other antihypertensive agents in terms of blood pressure reduction, its effects on mortality and long-term morbidity are currently unknown.
Description: Cost of Aliskiren per 1000 patients
Sub-ICB Locations are ordered by mean percentile over the past six months. Each chart shows the results for the individual Sub-ICB Location, plus deciles across all Sub-ICB Locations in the NHS in England.